文献速递痛风与晶体性关节病

URAT1/SLC22A12常见与罕见功能缺陷变异赋予显著抗痛风效应

Substantial anti-gout effect conferred by common and rare dysfunctional variants of URAT1/SLC22A12.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该研究对480例日本男性临床定义痛风病例和480例对照进行靶向外显子测序,并结合新发现URAT1变异的功能分析,发现URAT1常见与罕见功能缺陷变异均显著降低痛风风险(OR 0.0338,倒数OR 29.6,P = 7.66 × 10-8),且该保护效应超过ABCG2相关致病效应(OR 2.30-3.32)。

要点

  • URAT1常见变异rs121907892(p.W258X)与罕见功能缺陷变异均显著降低痛风风险。
  • URAT1相关保护效应超过ABCG2相关致病效应,即使存在ABCG2致病变异。
  • 研究支持「常见病,多个常见与罕见变异」的遗传模型。

核心结论

  • URAT1/SLC22A12的常见与罕见功能缺陷变异对痛风具有显著抗痛风效应,降低痛风风险。
  • URAT1相关保护效应超过ABCG2相关致病效应,提示URAT1变异在痛风遗传病因中具有重要作用。

研究设计与样本

  • 研究对480例临床定义痛风病例和480例对照的日本男性进行靶向外显子测序,并结合新发现URAT1变异的功能分析。

主要发现

  • URAT1常见与罕见功能缺陷变异显著降低痛风风险(OR 0.0338,倒数OR 29.6,P = 7.66 × 10-8)。
  • URAT1相关保护效应超过ABCG2相关致病效应(OR 2.30-3.32)。
  • 仅一个URAT1功能缺陷变异即可在存在ABCG2致病变异时表现出显著抗痛风效应。

关键数值与推荐

  • URAT1变异降低痛风风险的OR为0.0338(倒数OR 29.6,P = 7.66 × 10-8)。
  • ABCG2相关致病效应的OR范围为2.30-3.32。

临床怎么用

  • URAT1功能缺陷变异可作为痛风风险分层与个体化健康管理的遗传标志。
  • 在痛风遗传评估中应同时考虑URAT1的保护性变异与ABCG2的致病性变异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Gout, caused by chronic elevation of serum uric acid levels, is the commonest form of inflammatory arthritis. The causative effect of common and rare variants of ATP-binding cassette transporter G2 (ABCG2/BCRP) on gout risk has been studied, but little attention has been paid to the effect of common (rs121907892, p.W258X) and rare variants of urate transporter 1 (URAT1/SLC22A12) on gout, despite dysfunctional variants of URAT1 having been identified as pathophysiological causes of renal hypouricaemia. METHODS: To address this important but overlooked issue, we investigated the effects of these URAT1 variants on gout susceptibility, using targeted exon sequencing on 480 clinically defined gout cases and 480 controls of Japanese males in combination with a series of functional analyses of newly identified URAT1 variants. RESULTS: Our results show that both common and rare dysfunctional variants of URAT1 markedly decrease the risk of gout (OR 0.0338, reciprocal OR 29.6, P = 7.66 × 10-8). Interestingly, we also found that the URAT1-related protective effect on gout eclipsed the ABCG2-related causative effect (OR 2.30-3.32). Our findings reveal only one dysfunctional variant of URAT1 to have a substantial anti-gout effect, even in the presence of causative variants of ABCG2, a 'gout gene'. CONCLUSION: Our findings provide a better understanding of gout/hyperuricaemia and its aetiology that is highly relevant to personalized health care. The substantial anti-gout effect of common and rare variants of URAT1 identified in the present study support the genetic concept of a 'Common Disease, Multiple Common and Rare Variant' model.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Toyoda Y, Kawamura Y, Nakayama A, et al. Substantial anti-gout effect conferred by common and rare dysfunctional variants of URAT1/SLC22A12. Rheumatology (Oxford). 2021. PMID: 33821957. doi:10.1093/rheumatology/keab327

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。